Skip to content
Search

Latest Stories

UCL proposes simple daily pill that prevents heart attacks and strokes

Moving from treatment to prevention on a grand scale.

daily pill

This new approach could make life-saving medication accessible to millions

iStock

Imagine a single daily pill that could dramatically cut your risk of heart attacks and strokes. Sounds almost too good to be true, right? Well, scientists from University College London (UCL) believe this vision could soon be a reality. The breakthrough "polypill" combines a statin and three blood pressure-lowering medications, promising to transform how we prevent cardiovascular diseases, one of the UK’s biggest health challenges.

A revolutionary approach to heart disease prevention


Heart disease and strokes are silent killers, claiming thousands of lives each year. The current NHS Health Check programme helps identify at-risk individuals, but the system isn’t reaching nearly enough people. Fewer than half of those eligible even attend their appointments. This means that countless lives could be saved if more people were offered preventive treatment.

That’s where the polypill comes in. Rather than relying on complex risk assessments, UCL experts suggest a much simpler approach: offering the polypill to everyone aged 50 and over. No lengthy health checks, just the pill. This could make it a revolutionary tool in preventing heart attacks and strokes on a massive scale.

What exactly is the polypill?

The polypill is a combination of four well-established drugs: a statin to lower cholesterol and three different blood pressure-lowering medications. The idea of combining these drugs isn’t new; it dates back to a 2003 study that suggested a polypill could prevent up to 80% of heart attacks and strokes in people over 55. Since then, various trials have backed up these claims.

Professor Aroon Hingorani, a leading UCL researcher, explains that most heart attacks and strokes happen in people with “average” risk levels, which means the current system of identifying high-risk individuals often misses the mark. Offering the polypill to everyone over 50 could potentially save far more lives.

A simple, life-saving solution

One of the biggest advantages of the polypill is its simplicity. There’s no need for complicated medical assessments, just a few basic questions to check for side effects. Once that’s done, eligible people can start taking the pill, drastically reducing their risk of heart-related problems.

UCL researchers estimate that even if only 8% of people over 50 take up the offer, the health benefits would far exceed what’s currently achieved through the NHS Health Check. This new approach could make life-saving medication accessible to millions in the same way that vaccines or folic acid fortification do.

Professor Sir Nicholas Wald, another UCL co-author, compares the polypill approach to other public health programmes designed to prevent illness before it happens. “This isn’t about medicalising half the population,” Wald points out. “It’s about making sure people don’t become patients in the first place.”

Affordable, proven, and effective

The polypill is not only effective but also affordable. The medications it contains are all off-patent, meaning they’re inexpensive to produce. Despite the low cost, these drugs have a long-standing track record of success with minimal side effects. In particular, combining three blood pressure drugs at low doses reduces the risk of side effects even further while maximising the benefits.

In 2019, a landmark study in rural Iran showed that taking the polypill for five years reduced heart attacks and strokes by a third. This dramatic finding demonstrates the real-world potential of the polypill to change the game not just in the UK but globally.

What’s next for the polypill?

With such compelling evidence, the next step is figuring out how to introduce the polypill programme nationwide. UCL researchers have proposed a pilot project to evaluate how best to roll it out, looking at factors such as cost, uptake, and long-term effectiveness.

However, for this plan to become a reality, it would require policy changes. Currently, local authorities are required to offer NHS Health Checks, and a polypill programme would need to replace or supplement this. But the UCL team is confident this shift is necessary, calling the current situation “untenable.”

With over seven million people in the UK affected by cardiovascular disease, and more than 200,000 heart attacks and strokes every year, it’s clear that a new approach is desperately needed. The polypill could be that solution: a simple, affordable, and effective way to prevent countless deaths and reduce the burden on the NHS.

A new era in prevention

The polypill isn’t just another medical treatment; it could be the key to unlocking a future with fewer heart attacks and strokes. By offering this life-saving pill to everyone over 50, we could see a drastic reduction in cardiovascular diseases. The scientific evidence is strong, the potential impact is huge, and the time to act is now.

As we wait for further studies and potential rollouts, one thing is certain: prevention is always better than cure, and the polypill could very well be the future of heart disease prevention.

More For You

Asian community

Menopause is a universal transition - one every woman will experience in her lifetime

iStock

Breaking the silence: Why Asian women must talk about menopause

Kiran Singh

For many women in the Asian community, the journey through perimenopause and menopause is still shrouded in silence, confusion, and, at times, shame. It’s often seen as something we just have to “put up with” quietly, as though struggling through it alone is a badge of honour. But the truth is, menopause is a universal transition - one every woman will experience in her lifetime - and it is time we start talking about it, especially within our cultural communities where silence often masks suffering.

We all go through it - so why don’t we talk about it?

Menopause doesn’t arrive overnight. For most women, it begins subtly during perimenopause, which can start as early as your late 30s or early 40s and last for several years. According to the NHS and the National Institute for Health and Care Excellence (NICE), over 30 recognised symptoms of perimenopause range from hot flushes and night sweats to anxiety, low mood, brain fog, and joint pain.

Keep ReadingShow less
Great guide to building healthy eating habits

Good nutrition is the foundation of an active lifestyle

Great guide to building healthy eating habits

Nesreen G and Jayeeta Dutta

PHYSICAL exercise is important when it comes to fitness, but what we fuel our body with plays an equally vital role in achieving sustainable results.

The key to long-term fitness success is developing mindful eating habits that nourish the body and soul, enhance performance and help maintain a healthy lifestyle. This does not necessarily mean following a restrictive diet or complicated meal plans. It is about finding a sustainable balance that works for you.

Keep ReadingShow less
The Chase’s Paul Sinha shares Parkinson’s update after major health scare

Sinha’s message was one of resilience and realism

Getty

The Chase’s Paul Sinha shares Parkinson’s update after major health scare

Paul Sinha, known to viewers of ITV’s The Chase as “The Sinnerman,” has spoken candidly about his experience living with Parkinson’s disease. During an appearance on Loose Women on Thursday, 17 April, the comedian and quizzer reflected on his journey from diagnosis to managing the condition day to day.

Sinha, who was diagnosed with the progressive neurological disorder in 2019, revealed that his earliest symptoms were not what many would typically associate with Parkinson’s.

Keep ReadingShow less
Capivasertib: New NHS Pill Slows Incurable Breast Cancer Progression

Around 3,000 women each year could benefit from the treatment

iStock

New pill Capivasertib slows incurable breast cancer progression, now on NHS

A new drug for one of the most common forms of advanced breast cancer, capivasertib, is now available on the NHS in England. Around 3,000 women each year could benefit from the treatment after clinical trials showed it can slow the progression of the disease and shrink tumours in a significant number of patients.

The National Institute for Health and Care Excellence (NICE) has approved capivasertib for NHS funding. It is one of a range of treatment options offered to patients whose breast cancer has spread and is no longer curable.

Keep ReadingShow less
Eric Dane

There is currently no cure for ALS

Getty

Grey’s Anatomy and Euphoria star Eric Dane diagnosed with ALS

Eric Dane, best known for his roles in Grey’s Anatomy and Euphoria, has revealed he has been diagnosed with amyotrophic lateral sclerosis (ALS).

ALS, also referred to as motor neurone disease (MND) in the UK, is an incurable condition that progressively damages nerve cells in the brain and spinal cord, leading to increasing muscle paralysis. The disease affects around 153,000 people in the UK, though awareness of its wider range of symptoms remains relatively low.

Keep ReadingShow less